Onc Club | Articles

Meta-Analysis Reveals Potential Role of Clonal Hematopoiesis on Allogeneic and Autologous HSCT Outcomes

September 27th 2024

Shyam A. Patel, MD, PhD, discusses findings from a meta-analysis of the effect of clonal hematopoiesis on outcomes for hematopoietic stem cell transplant.

Disadvantaged Neighborhoods, Modifiable Chronic Health Conditions Are Associated With Late Deaths in Survivors of Childhood Cancer

March 22nd 2023

Living in a socioeconomically disadvantaged neighborhood or living with modifiable chronic health conditions were associated with an increased risk for death 5 years of more following diagnosis among survivors of childhood cancer, according to findings from a cohort study.

Post-Transplant KRd Maintenance May Allow for Superior Outcomes in Newly Diagnosed Multiple Myeloma

February 3rd 2023

Andrzej Jakubowiak, MD, PhD, highlighted several key studies that influenced the development and design of the ATLAS trial, introduced conclusions from the initial efficacy data, and discussed how ongoing analysis could further contextualize and inform post-transplant treatment approaches in multiple myeloma.

Pembrolizumab/Cabozantinib Combo Shows Promising Clinical Benefit in Recurrent Metastatic HNSCC

November 9th 2022

Nabil F. Saba, MD, FACP, expanded on efficacy data from a phase 2 trial investigating pembrolizumab plus cabozantinib in patients with recurrent metastatic head and neck squamous cell carcinoma and current challenges and safety concerns in selecting patients for evaluation.

Neoadjuvant mFOLFIRINOX Exceeds Historical OS Rates in Pancreatic Cancer

August 10th 2022

Matthew H. G. Katz, MD, CMQ, FACS, FASCO, discusses the use of neoadjuvant mFOLFIRINOX in patients with borderline resectable pancreatic cancer.

Poziotinib Elicits Encouraging Responses in EGFR Exon 20–Mutated NSCLC

August 2nd 2022

Poziotinib produced an encouraging overall response rate in patients with non–small cell lung cancer harboring EGFR exon 20 mutations, meeting the primary end point in cohort 1 of a phase 2 trial.

Neoadjuvant mFOLFIRINOX Produces Favorable OS Results Without Radiation in Borderline Resectable Pancreatic Cancer

July 27th 2022

Neoadjuvant mFOLFIRINOX induced favorable overall survival results for patients with borderline resectable pancreatic ductal adenocarcinoma when administered prior to pancreatectomy, though neoadjuvant mFOLFIRINOX followed by hypofractionated radiation therapy did not prove to be similarly effective.

COVID-19 Vaccination Strategies Should Consider Infection Risks for CAR T-Cell Therapy Recipients

October 28th 2021

Although CAR T-cell therapies have demonstrated unprecedented activity in patients with heavily pretreated relapsed/refractory hematologic malignancies, they are marked by a significant risk of infections and may limit the efficacy of COVID-19 vaccines.

Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic

August 16th 2021

COVID-19 vaccination has been shown to induce high rates of seroconversion in patients with cancer, although those with hematologic malignancies have demonstrated lower immunogenicity and those who previously received immunosuppressive therapies appear to be less responsive.

Landgren Spotlights Safety Considerations for Carfilzomib Quadruplet in Newly Diagnosed Myeloma

June 17th 2021

C. Ola Landgren, MD, PhD, discusses key safety considerations with a novel carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, the clinical implications of the phase 2 MANHATTAN trial, and next steps for this research.

Whole-Genome Sequencing in Smoldering Myeloma and MGUS Could Predict Outcomes

May 12th 2021

Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.